Search results
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 3 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoTruqap™ (capivasertib) plus fulvestrant now available in Canada Canada NewsWire MISSISSAUGA, ON, May 31, 2024 MISSISSAUGA, ON, May 31, 2024 /CNW/ - AstraZeneca is pleased ...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 4 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
Cramer's Lighting Round: ‘You've got a winner' with Astra Zeneca
NBC Los Angeles· 6 days ago“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to...
Health Care Roundup: Market Talk
The Wall Street Journal· 7 days agoKeytruda is the world’s top-selling drug and raked in about $25 billion in revenue for Merck last year. (ben.glickman@wsj.com; @benglickman) 1151 ET – ...
Docs Endorsing Products on X May Not Disclose Company Ties
Medscape· 7 hours agoNearly one in three physicians endorsing drugs and devices on the social media platform X did not...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WSAU Wausau· 4 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks via Yahoo Finance· 6 days agoJ&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority...
Is Semaglutide the
Medscape· 3 days agoThere has been much hyperbole since the presentation of results from the SELECT cardiovascular outcomes trial (CVOT) at this year's European Congress on...
BofA: Top corporate bond ideas list for June
Investing.com· 3 days agoBofA: Top corporate bond ideas list for June